» Articles » PMID: 16126266

Potent Suppression of Natural Killer Cell Response Mediated by the Ovarian Tumor Marker CA125

Overview
Journal Gynecol Oncol
Date 2005 Aug 30
PMID 16126266
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: CA125 expresses specific oligosaccharides that can inhibit the cytotoxicity of human natural killer (NK) cells. The current study was undertaken to determine the ability of CA125 to modulate NK cell-mediated cytotoxicity.

Methods: CA125 was isolated from OVCAR-3 cells and its purity was determined by ELISA and ultra-sensitive mass spectrometric analysis. Peripheral blood-derived NK were treated with CA125 and standard cytotoxicity assays were performed using 51Cr-labeled K562 cells as targets. The expression of cell surface and intracellular markers on NK cells was determined by either flow cytometry or Western blot analysis.

Results: NK cells incubated with CA125 for 72 h exhibited a 50-70% decrease in the lysis of K562 targets. Incubation with CA125 for 4 h and 24 h had no effect on NK-mediated cytolysis. Inhibition of NK function was observed at CA125 concentrations (10,000-100,000 U/ml) that are expected to be significantly lower than those observed in the tumor microenvironment. Co-stimulation with IL-2 did not abrogate the NK inhibitory response of CA125. CA125 did not reduce proliferation or induce apoptosis of NK cells and alter the expression of p56lck, phospholipase Cgamma1, ZAP70, or CD3zeta. CA125 did, however, induce major downregulation of CD16 and minor decrease in expression of CD94/NKG2A.

Conclusions: Our ongoing research and recent work performed by other laboratories highlights the potential physiologic role of this mucin. Based on the data presented here, it is likely that the tumor-derived CA125 acts as a suppressor of the immune response that is directed against the ovarian tumors.

Citing Articles

Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study.

Guo G, Zhang Z, Zhang J, Wang D, Xu S, Wu S Cancer Med. 2025; 14(5):e70733.

PMID: 40022576 PMC: 11871513. DOI: 10.1002/cam4.70733.


The emergence of DNAM-1 as the facilitator of NK cell-mediated killing in ovarian cancer.

Pounds R, Croft W, Pearce H, Hossain T, Singh K, Balega J Front Immunol. 2025; 15():1477781.

PMID: 39835114 PMC: 11743932. DOI: 10.3389/fimmu.2024.1477781.


Increased peritoneal TGF-β1 is associated with ascites-induced NK-cell dysfunction and reduced survival in high-grade epithelial ovarian cancer.

Maas R, Hoogstad-van Evert J, Hagemans I, Brummelman J, van Ens D, de Jonge P Front Immunol. 2024; 15:1448041.

PMID: 39376560 PMC: 11456434. DOI: 10.3389/fimmu.2024.1448041.


Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas.

Kaur K, Sanghu J, Memarzadeh S, Jewett A Vaccines (Basel). 2024; 12(6).

PMID: 38932405 PMC: 11209217. DOI: 10.3390/vaccines12060677.


Effect of different treatment modalities on the prognosis of stage IV epithelial ovarian cancer: analysis of the SEER database.

Zhang S, Zhang H, Jia N, Suo S, Guo J BMC Womens Health. 2024; 24(1):345.

PMID: 38877551 PMC: 11179217. DOI: 10.1186/s12905-024-03199-5.